LUYE MEDICAL GROUP PTE. LTD.

Luye Medical Group is a top 10 private healthcare services provider in the Asia Pacific with global footprint across Australia, China and Singapore. By embracing digital health adoption to enhance clinical outcomes, patient engagement and operational efficiency, we aim to be a leader in high-growth specialities including integrated cancer care, rehabilitation, cardiology and mental health. Luye Medical Group is part of the larger Luye Life Sciences Group. Established in 1994, the Group comprises of four core businesses, Luye Pharma, Luye Medical, Luye Diagnostics as well as new technology investment and development. The Group’s products and services spread across over 80 countries and regions around the world.

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas. Along with a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. and Europe, Luye Pharma has reached high-level international standards in advanced drug delivery technologies including microspheres, liposomes and transdermal drug delivery systems, as well as actively making strategic developments in the fields of innovative new compounds and antibodies, gene & cell therapies and smart formulations. Luye Pharma is developing a global supply chain of 7 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. With more than 30 products covering the 4 largest and fastest growing therapeutic areas — oncology, cardiovascular, metabolism and central nervous system, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., Europe and Japan, as well as in fast growing emerging markets.